Preemptive drug DEC-C after transplant to reduce hidden cancer
Part of Blood & lymphatic clinical trials.
This trial tests whether giving DEC-C (a decitabine-based treatment) soon after an allogeneic transplant can improve outcomes for MDS patients who still have “measurable residual disease” (hidden leftover disease) detectable by a genetic test. It also compares this approach to standard observation if the hidden disease is not detected or if the higher-risk safety checks are not met.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MDS and had an allogeneic stem cell transplant (from a donor).
- You’re between 18 and 75 years old.
- Before transplant, you had gene-panel testing, and it found mutations that the trial’s test can track.
- At about Day 30 after transplant, you must have a plan to follow the study’s treatment assignment (DEC-C if eligible, or observation if not).
- You must be well enough and have blood counts and organ function that meet the study safety thresholds for the DEC-C arm.
- If you could become pregnant, you must use reliable birth control (and not be pregnant or breastfeeding).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a personalized lab test to detect small amounts of disease after a stem cell transplant and then decide what treatment comes next. It may help some people with certain bone-marrow diseases stay in remission while avoiding unnecessary treatment.
This Phase 1 trial tests whether SX-682 given alone or with decitabine can treat myelodysplastic syndrome (MDS) that has not responded well to prior therapy. It also studies safety and the best dose, which may help people who have limited treatment options.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This trial tests a stem cell transplant that uses specially selected cells (CD34+ cells) to treat myelodysplastic syndrome (MDS), a blood disorder. The transplant comes from a donor and aims to replace unhealthy blood-forming cells with healthy ones, which may slow or stop the disease. It is designed for patients with higher-risk MDS or certain high-risk features.
This trial tests a new approach to reduce the chance of leukemia or other blood cancers coming back after a stem cell transplant. It uses careful monitoring before the transplant to try to prevent relapse.
This trial tests a new combination of two drugs—leflunomide and decitabine—for people with MDS that has come back or hasn't responded to treatment. The goal is to see if this combination can help control the disease.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.